John Gray - Vertex Pharmaceuticals Senior Vice President Genetic Therapies

VRTX -- USA Stock  

Quarterly Earning Report: October 23, 2019  

  President
We currently do not have informatin regarding John Gray. This executive tanure with Vertex Pharmaceuticals Incorpor is not currenlty determined.
Age: 53  President Since 2019      
617 341-6100  www.vrtx.com

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95 M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Jeffrey NeedhamPerrigo Company Plc
2009
Marc CouckePerrigo Company Plc
N/A
Jay MarkowitzRegeneron Pharmaceuticals
2017
John WesolowskiPerrigo Company Plc
2016
Jatin ShahPerrigo Company Plc
2005
Louis YuPerrigo Company Plc
2013
Paul WeningerPerrigo Company Plc
2015
Raghav ChariDr Reddys Laboratories Ltd
2013
Grainne QuinnPerrigo Company Plc
2016
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Thomas FarringtonPerrigo Company Plc
2015
J RamachandranDr Reddys Laboratories Ltd
2016
George YancopoulosRegeneron Pharmaceuticals
2016
Clinton LewisZoetis
2018
Cartikeya ReddyDr Reddys Laboratories Ltd
2016
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Stefan WeiskopfZoetis
2013
Svend AndersenPerrigo Company Plc
2017
Michael AbermanRegeneron Pharmaceuticals
2015
Samiran DasDr Reddys Laboratories Ltd
2016
Amit BiswasDr Reddys Laboratories Ltd
2016

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased few shares of
2 days ago
Traded for 177.06
Purchased over 300 shares of
2 days ago
Traded for 8.78
Purchased over 70 shares of
2 days ago
Traded for 35.57
Also please take a look at World Market Map. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Search macroaxis.com